Mirikizumab Sustains Four-Year Remission in Ulcerative Colitis Responders
Analysis Rheumatology / Immunology Confirmatory Grade: Low
Owens HN, Vázquez-Otero C, Arevalo M, et al.
Dec 7, 2026 · Published in: Human Vaccines & Immunotherapeutics
Also in Gastroenterology / Hepatology
Provider training can drive HPV vaccine uptake in young adults.
Sofosbuvir/Velpatasvir Handles Novel Hepatitis C Subtypes; Genotype 3b Remains a Concern
Analysis Infectious Disease / Antimicrobials Confirmatory Grade: Low
Han WM, Solomon S, Wagner-Cardoso S, et al.
Oct 24, 2026 · Published in: Journal of Viral Hepatitis
Also in Gastroenterology / Hepatology
SOF/VEL shows promise against diverse HCV genotypes, including novel subtypes.
Second-Line HCC After TKI Failure: Efficacy Versus Toxicity Network Analysis
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Li X, Nie G, Wang Y, et al.
Oct 24, 2026 · Published in: Frontiers in Immunology
Also in Gastroenterology / Hepatology
Pembrolizumab outshines others in post-TKI hepatocellular carcinoma treatment.
De-escalation in Severe Abdominal Sepsis: Association With Cure, Not Proof of Benefit
Analysis Infectious Disease / Antimicrobials Hypothesis-generating Grade: Low
Zhang L, Ye H
Oct 23, 2026 · Published in: BMC Infectious Diseases
Also in Critical Care / ICU, Gastroenterology / Hepatology
De-escalation boosts survival in severe intra-abdominal infections.
Subcutaneous Vedolizumab Holds Its Own Against Newer UC Therapies in Network Meta-Analysis
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Low
Jiang J, Wojtowicz A, Uyei J, et al.
Oct 22, 2026 · Published in: BMC Gastroenterology
Also in Gastroenterology / Hepatology
Vedolizumab SC shines in efficacy and safety for ulcerative colitis.
App-Guided Tapering Raises PPI Discontinuation From 64% to 86% Versus Brochure
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Low
Koggel LM, Timmers T, Lantinga MA, et al.
Oct 19, 2026 · Published in: United European Gastroenterology Journal
App proves superior in discontinuing unnecessary PPI use.
Sofosbuvir/Daclatasvir Matches Grazoprevir/Elbasvir at 100% SVR12 in Hemodialysis Hepatitis C
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Low
Sulaiman AS, Nugroho P, Bestari MB, et al.
Oct 8, 2026 · Published in: Acta Medica Indonesiana
Sofosbuvir/daclatasvir proves effective for hepatitis C in hemodialysis patients.
IBC Superior for Liver Metastasis in Lung Cancer
Analysis Gastroenterology / Hepatology
Li J, Ge Y, Liu Q, et al.
Oct 6, 2026 · Published in: Cancer Medicine
New treatments show promise for liver metastases in lung cancer.
Vedolizumab-First in UC Linked to More Steroid-Free Stability
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Low
Singh S, Söderling J, Forss A, et al.
Sep 25, 2026 · Published in: JAMA Network Open
Vedolizumab delivers better long-term stability in UC than TNF antagonists.
Biologics and JAK inhibitors show efficacy in Crohn's-associated orofacial granulomatosis
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Low
Lees RD, Patel P, Young G, et al.
Sep 22, 2026 · Published in: Journal of Crohn's & Colitis
Also in Rheumatology / Immunology
Biologics show promise for Crohn's disease with orofacial granulomatosis.
AASLD/IDSA 2025 Hepatitis B Guideline Shifts From Guidance to Recommendations
Guideline Infectious Disease / Antimicrobials Practice-changing Grade: Low
Nguyen MH
Sep 9, 2026 · Published in: Gastroenterology & Hepatology
Also in Gastroenterology / Hepatology
New guidelines reshape hepatitis B virus management strategies.
Short-Course Steroids Trigger HBV Reactivation in COVID-19
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Very Low
Öztürk Çerik H, Aldemir Ö, Katirci B, et al.
Sep 1, 2026 · Published in: Medicine
Screen for HBV before giving corticosteroids to COVID-19 patients.
Risankizumab in IBD: Effective but Evidence Uneven Across CD and UC
Analysis Gastroenterology / Hepatology Confirmatory Grade: Low
Afzal MW, Haseeb A, Ali U, et al.
Sep 1, 2026 · Published in: Medicine
Also in Rheumatology / Immunology
Risankizumab shows promise for challenging Crohn's and colitis cases.
Pediatric Peptic Ulcer Disease: Scope-and-Treat, Not Test-and-Treat
Analysis Pediatric Pharmacy Confirmatory Grade: Low
Martinez CA, Castillo P, Medina AL, et al.
Aug 31, 2026 · Published in: Pediatrics in Review
Also in Gastroenterology / Hepatology
Pediatric peptic ulcer disease demands tailored management strategies beyond adult protocols.
Bilirubin-Guided Voriconazole Dosing Improves Target Attainment in Liver Dysfunction
Analysis Pharmacokinetics / TDM Hypothesis-generating Grade: Low
Li J, Zhao Y, Liu H, et al.
Aug 27, 2026 · Published in: Frontiers in Pharmacology
Also in Gastroenterology / Hepatology
Optimized voriconazole dosing enhances outcomes in liver dysfunction.